OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.
Keywords: Exploratory studies; Injection paradigm; Migraine; Real-life studies; Technical issues.
Copyright © 2017 Elsevier Ltd. All rights reserved.